Clinical trial · Observational
MACSSI (MAstectomie Cellules Souches Surveillance Immunitaire)
Evaluation of Stem and Immune Cells in the Early Stage Breast Cancer Without Genetic Risk
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Monocentric, observational and prospective study in adult women having an early-stage breast cancer without genetic risk. The main objective is to characterize quantitatively and qualitatively, after solitary confinement, the resident breast stem cells and the immune system cells infiltrated in the mammary gland in women: * With a moderate risk of breast cancer progression (women with an early "Luminal A" tumor) = Group A. * With a high risk of breast cancer progression (women with an early "Luminal B" or basal tumor) = Group B.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Characterization of breast stem & immune system cells infiltrated in the mammary gland | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- To characterise quantitatively and qualitatively, after solitary confinement, the resident breast stem cells and the immune system cells infiltrated in the mammary gland according to the risk of breast cancer progression (group A and B)
- timeFrame
- Within one month after inclusion (date of surgery)
- description
- Rate of stem and immune cells and phenotype analysis
Secondary outcomes (6)
- measure
- Functional characterization, after solitary confinement, of stem cells and immune system cells from groups A and B
- timeFrame
- Within one month after inclusion (date of surgery)
- description
- Functional test: mammosphere
- measure
- Functional characterization, after solitary confinement, of stem cells and immune system cells from groups A and B
- timeFrame
- Within one month after inclusion (date of surgery)
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 18 years * Patient requiring a breast surgery (total mastectomy) of an early stage tumour classified as : * Luminal A (Arm A) : Patients with a moderate risk of breast cancer progression or, * Luminal B or Basal (Arm B) : Patients with a high risk of breast cancer progression * Systemic treatment not initiated * Breast cup size ≥ C * Informed and signed consent. Exclusion Criteria: * Neo-adjuvant chemotherapy or hormonotherapy * History of breast irradiation * Pregnant or breastfeeding woman * Patient under tutorship or curatorship * Patient who underwent a lumpectomy with a level-2 oncoplastic surgery (ex: breast reduction with an inverted-T remodeling) * Any other prior anti-tumor treatment * Other medical pathology which may interfere with the biologic evaluation, especially chronic auto-immune diseases.
References
Publications (0)
Data not yet available